Bloomberg News

Amicus Shares Fall on Drug Failure in Fabry Disease Study

December 20, 2012

Amicus Therapeutics Inc. (FOLD:US) shares fell the most ever after the company said its experimental treatment for Fabry disease failed in a clinical trial.

Amicus dropped 47 percent to $3.06 at 4 p.m. New York time, the biggest (FOLD:US) one-day drop since it began trading in 2007. Amicus, based in Cranbury, New Jersey, is developing the treatment with London-based drugmaker GlaxoSmithKline Plc. (GSK) The shares have fallen 11 percent this year.

Fabry disease is a rare genetic disorder in which patients can’t break down fats that accumulate in the body’s organs. A six-month result from the 67-patient trial showed that the experimental drug didn’t perform better than a placebo, Amicus and Glaxo said today in a statement. The study, in the third and final stage of testing typically required for regulatory approval, will continue for a full year, the companies said.

No serious adverse events were reported in the clinical trial, the companies said.

To contact the reporters on this story: Elizabeth Lopatto in New York at; Drew Armstrong in New York at

To contact the editor responsible for this story: Reg Gale at

Toyota's Hydrogen Man

Companies Mentioned

  • FOLD
    (Amicus Therapeutics Inc)
    • $8.03 USD
    • 0.15
    • 1.87%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus